CN1856476A - 异喹啉酮钾通道抑制剂 - Google Patents

异喹啉酮钾通道抑制剂 Download PDF

Info

Publication number
CN1856476A
CN1856476A CNA2004800273696A CN200480027369A CN1856476A CN 1856476 A CN1856476 A CN 1856476A CN A2004800273696 A CNA2004800273696 A CN A2004800273696A CN 200480027369 A CN200480027369 A CN 200480027369A CN 1856476 A CN1856476 A CN 1856476A
Authority
CN
China
Prior art keywords
phenyl
ketone
alkyl
replace
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2004800273696A
Other languages
English (en)
Chinese (zh)
Inventor
B·W·特罗特
C·克莱本
G·S·蓬蒂切洛
C·J·麦英泰尔
N·利弗汤
D·A·克莱尔蒙
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of CN1856476A publication Critical patent/CN1856476A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/03—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/04—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing a quinolizine ring system condensed with only one six-membered carbocyclic ring, e.g. julolidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
CNA2004800273696A 2003-09-23 2004-09-17 异喹啉酮钾通道抑制剂 Pending CN1856476A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50510103P 2003-09-23 2003-09-23
US60/505,101 2003-09-23

Publications (1)

Publication Number Publication Date
CN1856476A true CN1856476A (zh) 2006-11-01

Family

ID=34392976

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2004800273696A Pending CN1856476A (zh) 2003-09-23 2004-09-17 异喹啉酮钾通道抑制剂

Country Status (7)

Country Link
US (2) US7723352B2 (https=)
EP (1) EP1667982B1 (https=)
JP (1) JP4718467B2 (https=)
CN (1) CN1856476A (https=)
AU (1) AU2004276236B2 (https=)
CA (1) CA2539814C (https=)
WO (1) WO2005030791A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101573338B (zh) * 2006-12-27 2013-03-20 塞诺菲-安万特股份有限公司 环烷基胺取代的异喹诺酮和异喹啉酮衍生物

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1856473A (zh) * 2003-09-23 2006-11-01 默克公司 异喹啉酮钾通道抑制剂
JP4719151B2 (ja) * 2003-09-23 2011-07-06 メルク・シャープ・エンド・ドーム・コーポレイション イソキノリノンカリウムチャネル阻害剤
WO2005030726A1 (en) * 2003-09-23 2005-04-07 Merck & Co., Inc. Isoquinolinone potassium channel inhibitors
WO2005030791A2 (en) * 2003-09-23 2005-04-07 Merck & Co., Inc. Isoquinolinone potassium channel inhibitors
EP1667981A4 (en) * 2003-09-23 2008-08-13 Merck & Co Inc ISOCHINOLINE AS KALIUM CHANNEL INHIBITORS
US7723290B2 (en) 2004-10-22 2010-05-25 Bioincept, Llc Compositions and methods for modulating the immune system
US7879839B2 (en) 2004-07-29 2011-02-01 Merck Sharp & Dohme Corp. Potassium channel inhibitors
US7569589B2 (en) 2004-07-29 2009-08-04 Merck & Co., Inc. Potassium channel inhibitors
DE102005028862A1 (de) * 2005-06-22 2007-01-11 Sanofi-Aventis Deutschland Gmbh Substituierte Heterocyclen, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
NZ565040A (en) 2005-06-28 2010-05-28 Sanofi Aventis Isoquinoline derivatives as inhibitors of RHO-kinase
KR101373535B1 (ko) 2005-07-26 2014-03-12 사노피 Ｒｈｏ-키나제 억제제로서의 피페리디닐-치환된 이소퀴놀론유도체
JP5049970B2 (ja) 2005-07-26 2012-10-17 サノフイ Ｒｈｏ−キナーゼ阻害剤としてのシクロヘキシルアミンイソキノロン誘導体
GB0525164D0 (en) 2005-12-09 2006-01-18 Xention Discovery Ltd Compounds
AU2007217099A1 (en) * 2006-02-17 2007-08-30 Janssen Pharmaceutica N.V. Pyrazolylquinazolinones as potassium channel openers
RU2455302C2 (ru) 2006-12-27 2012-07-10 Санофи-Авентис ЗАМЕЩЕННЫЕ ИЗОХИНОЛИНОВЫЕ И ИЗОХИНОЛИНОНОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Rho-КИНАЗЫ
EP2114920A1 (en) 2006-12-27 2009-11-11 Sanofi-Aventis Substituted isoquinoline and isoquinolinone derivatives
KR20090092303A (ko) * 2006-12-27 2009-08-31 사노피-아벤티스 사이클로알킬아민 치환된 이소퀴놀린 유도체
RU2468011C2 (ru) 2006-12-27 2012-11-27 Санофи-Авентис Замещенные циклоалкиламином производные изохинолина и изохинолинона
WO2008077555A2 (en) 2006-12-27 2008-07-03 Sanofi-Aventis Substituted isoquinolines and their use as rho-kinase inhibitors
NZ577980A (en) 2006-12-27 2012-01-12 Sanofi Aventis Cycloalkylamine substituted isoquinolone derivatives
ES2475193T3 (es) 2007-01-22 2014-07-10 Gtx, Inc. Agentes de unión al receptor nuclear
US9604931B2 (en) 2007-01-22 2017-03-28 Gtx, Inc. Nuclear receptor binding agents
US9623021B2 (en) * 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
CN102131784B (zh) 2008-06-24 2014-08-27 赛诺菲-安万特 作为rho激酶抑制剂的取代的异喹啉和异喹啉酮
HRP20131040T1 (hr) 2008-06-24 2013-12-06 Sanofi Bi- i policikliäśki supstituirani izokinolin i derivati izokinolina kao inhibitori rho-kinaze
PT2313374E (pt) 2008-06-24 2013-11-29 Sanofi Sa Isoquinolinas e isoquinolinonas 6-substituídas
GB0815784D0 (en) 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
GB0815781D0 (en) 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
GB0815782D0 (en) 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
US9737585B2 (en) 2011-03-02 2017-08-22 Bioincept, Llc Compositions and methods for treatment of intracellular damage and bacterial infection
WO2013142390A1 (en) * 2012-03-21 2013-09-26 Gtx, Inc. Aldo-keto reductase subfamily 1c3 (akr1c3) inhibitors
WO2017039751A1 (en) 2015-08-28 2017-03-09 Bioincept, Llc Mutant peptides and methods of treating subjects using the same
EP3290407B1 (en) 2013-10-18 2020-01-01 Celgene Quanticel Research, Inc Bromodomain inhibitors
EA038715B1 (ru) * 2014-01-24 2021-10-08 Селджен Квонтисел Рисёрч, Инк. Ингибиторы бромодомена
AR104259A1 (es) 2015-04-15 2017-07-05 Celgene Quanticel Res Inc Inhibidores de bromodominio
AU2016317574A1 (en) 2015-08-28 2018-03-29 Bioincept, Llc Compositions and methods for the treatment of neurodamage
AU2017252276A1 (en) 2016-04-18 2018-11-15 Celgene Quanticel Research, Inc. Therapeutic compounds
US10150754B2 (en) 2016-04-19 2018-12-11 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
WO2021203014A1 (en) 2020-04-03 2021-10-07 Vertex Pharmaceuticals Incorporated Pyrano[4,3-b]l ndole derivatives as alpha-1 -antitrypsin modulators for treating alpha-1 -antitrypsin deficiency (aatd)
EP4126819A1 (en) * 2020-04-03 2023-02-08 Vertex Pharmaceuticals Incorporated 7- or 8-hydroxy-isoquinoline and 7- or 8-hydroxy-quinoline derivatives as alpha-1 -antitrypsin modulators for treating alpha-1 -antitrypsin deficiency (aatd)

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3594380A (en) * 1969-02-18 1971-07-20 American Home Prod Isoquinolin-1(2h)-ones
US3878215A (en) * 1971-12-01 1975-04-15 Sandoz Ag 2-Alkyl-3-substituted-4-aryl isoquinolines
US4897391A (en) * 1988-06-17 1990-01-30 Schering Corporation Tricyclic anti-allergy, antiinflammatory and anti-hyperproliferative compounds
EP0585913B1 (en) * 1992-09-04 1997-12-29 Takeda Chemical Industries, Ltd. Condensed heterocyclic compounds, their production and use
AU5772196A (en) 1995-05-19 1996-11-29 Chiroscience Limited 3,4-disubstituted-phenylsulphonamides and their therapeutic use
EP1322619B1 (en) * 2000-09-20 2008-01-23 Merck & Co., Inc. Isoquinolinone potassium channel inhibitors
JPWO2002094790A1 (ja) 2001-05-23 2004-09-09 三菱ウェルファーマ株式会社 縮合ヘテロ環化合物およびその医薬用途
AU2003211931A1 (en) 2002-02-13 2003-09-04 Takeda Chemical Industries, Ltd. Jnk inhibitor
EP1667981A4 (en) * 2003-09-23 2008-08-13 Merck & Co Inc ISOCHINOLINE AS KALIUM CHANNEL INHIBITORS
WO2005030726A1 (en) * 2003-09-23 2005-04-07 Merck & Co., Inc. Isoquinolinone potassium channel inhibitors
CN1856473A (zh) * 2003-09-23 2006-11-01 默克公司 异喹啉酮钾通道抑制剂
WO2005030791A2 (en) * 2003-09-23 2005-04-07 Merck & Co., Inc. Isoquinolinone potassium channel inhibitors
JP4719151B2 (ja) * 2003-09-23 2011-07-06 メルク・シャープ・エンド・ドーム・コーポレイション イソキノリノンカリウムチャネル阻害剤

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101573338B (zh) * 2006-12-27 2013-03-20 塞诺菲-安万特股份有限公司 环烷基胺取代的异喹诺酮和异喹啉酮衍生物

Also Published As

Publication number Publication date
EP1667982A2 (en) 2006-06-14
WO2005030791A3 (en) 2005-05-26
CA2539814C (en) 2010-07-06
AU2004276236A1 (en) 2005-04-07
CA2539814A1 (en) 2005-04-07
US8338449B2 (en) 2012-12-25
EP1667982B1 (en) 2013-07-31
US20070027177A1 (en) 2007-02-01
EP1667982A4 (en) 2008-08-13
JP4718467B2 (ja) 2011-07-06
AU2004276236B2 (en) 2008-01-24
US20100256698A1 (en) 2010-10-07
US7723352B2 (en) 2010-05-25
WO2005030791A2 (en) 2005-04-07
JP2007516218A (ja) 2007-06-21

Similar Documents

Publication Publication Date Title
CN1856476A (zh) 异喹啉酮钾通道抑制剂
CN1856307A (zh) 喹啉钾通道抑制剂
CN100337626C (zh) 酰化的、杂芳基－稠合的环烯基胺和它们作为药物的用途
CN1151136C (zh) 缩合哒嗪系化合物
CN1856474A (zh) 异喹啉钾通道抑制剂
CN1273451C (zh) 哌啶mch拮抗剂及其治疗肥胖症的用途
CN1856475A (zh) 异喹啉钾通道抑制剂
CN1191249C (zh) 用于治疗、特别是治疗良性前列腺增生的喹啉和喹唑啉化合物
CN1993347A (zh) 钾通道抑制剂
HK1040712A1 (en) Substituted pyrazole derivatives condensed with six-membered heterocyclic rings
CN1960975A (zh) 作为多聚(adp－核糖)聚合酶(parp)抑制剂的取代的吡啶酮
CN1950371A (zh) 用作组胺h3受体配体的四氢萘啶衍生物
CN101031559A (zh) 氨基环脲衍生物和其制法及作为激酶抑制剂的医药用途
CN1856477A (zh) 异喹啉钾通道抑制剂
CN1351497A (zh) 用作山梨醇脱氢酶抑制剂的氨基嘧啶类化合物
CN1688577A (zh) 三氮杂螺[5.5]十一烷衍生物及以它为活性成分的药物
CN1665811A (zh) 氨基甲酸酯－取代的吡唑并吡啶类化合物
CN1675209A (zh) 二氢吡唑并吡啶化合物
CN1856473A (zh) 异喹啉酮钾通道抑制剂
CN1856310A (zh) 喹唑啉钾通道抑制剂
CN1127498C (zh) 吡啶衍生物、制备吡啶衍生物的方法及其中间体
CN1968929A (zh) 取代的四氢－2h－异喹啉－1－酮衍生物、其制备方法以及其作为药物的用途
CN1202171A (zh) 吡啶并[2,3－d]嘧啶衍生物及其医药组合物
CN1886402A (zh) 嘧啶－2－胺衍生物及其作为a2b腺苷受体拮抗剂的用途
CN1816541A (zh) Vr－1拮抗剂取代－1－酞嗪胺

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication